Press releases
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.28 |
---|---|
High | 2.28 |
Low | 2.28 |
Bid | 2.18 |
Offer | 2.24 |
Previous close | 2.28 |
Average volume | -- |
---|---|
Shares outstanding | 175.40m |
Free float | 171.71m |
P/E (TTM) | -- |
Market cap | 191.19m USD |
EPS (TTM) | -0.1444 USD |
Data delayed at least 15 minutes, as of May 06 2022.
More ▼